Astaxanthin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Astaxanthin
Accession Number
DB06543
Description

Astaxanthin is a keto-carotenoid in the terpenes class of chemical compounds. It is classified as a xanthophyll but it is a carotenoid with no vitamin A activity. It is found in the majority of aquatic organisms with red pigment. Astaxanthin has shown to mediate anti-oxidant and anti-inflammatory actions. It may be found in fish feed or some animal food as a color additive.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 596.852
Monoisotopic: 596.386560154
Chemical Formula
C40H52O4
Synonyms
Not Available

Pharmacology

Indication

Investigated for use/treatment in eye disorders/infections, cancer/tumors (unspecified), and asthma.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UNF-kappa-B inhibitor alphaNot AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Astaxanthin.
AceclofenacThe risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Astaxanthin.
AcemetacinThe risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Astaxanthin.
AcenocoumarolThe risk or severity of bleeding can be increased when Acenocoumarol is combined with Astaxanthin.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Astaxanthin.
Albutrepenonacog alfaThe therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Astaxanthin.
AlclofenacThe risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Astaxanthin.
AldesleukinThe risk or severity of bleeding can be increased when Astaxanthin is combined with Aldesleukin.
AlemtuzumabThe risk or severity of bleeding can be increased when Astaxanthin is combined with Alemtuzumab.
AlteplaseThe risk or severity of bleeding can be increased when Astaxanthin is combined with Alteplase.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

Purchasing individual compounds or compound libraries for your research?
Learn More

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as xanthophylls. These are carotenoids containing an oxygenated carotene backbone. Carotenes are characterized by the presence of two end-groups (mostly cyclohexene rings, but also cyclopentene rings or acyclic groups) linked by a long branched alkyl chain. Carotenes belonging form a subgroup of the carotenoids family. Xanthophylls arise by oxygenation of the carotene backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Tetraterpenoids
Direct Parent
Xanthophylls
Alternative Parents
Cyclohexenones / Secondary alcohols / Organic oxides / Hydrocarbon derivatives
Substituents
Alcohol / Aliphatic homomonocyclic compound / Carbonyl group / Cyclic ketone / Cyclohexenone / Hydrocarbon derivative / Ketone / Organic oxide / Organic oxygen compound / Organooxygen compound
Molecular Framework
Aliphatic homomonocyclic compounds
External Descriptors
carotenone, carotenol (CHEBI:40968) / C40 isoprenoids (tetraterpenes), Carotenoids (C08580) / C40 isoprenoids (tetraterpenes) (LMPR01070263)

Chemical Identifiers

UNII
8XPW32PR7I
CAS number
472-61-7
InChI Key
MQZIGYBFDRPAKN-UWFIBFSHSA-N
InChI
InChI=1S/C40H52O4/c1-27(17-13-19-29(3)21-23-33-31(5)37(43)35(41)25-39(33,7)8)15-11-12-16-28(2)18-14-20-30(4)22-24-34-32(6)38(44)36(42)26-40(34,9)10/h11-24,35-36,41-42H,25-26H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,27-15+,28-16+,29-19+,30-20+/t35-,36-/m0/s1
IUPAC Name
(6S)-6-hydroxy-3-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4S)-4-hydroxy-2,6,6-trimethyl-3-oxocyclohex-1-en-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-2,4,4-trimethylcyclohex-2-en-1-one
SMILES
C\C(\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[[email protected]@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C(=O)[[email protected]@H](O)CC1(C)C

References

General References
Not Available
Human Metabolome Database
HMDB0002204
KEGG Compound
C08580
PubChem Compound
5281224
PubChem Substance
347827776
ChemSpider
4444636
RxNav
18451
ChEBI
40968
ChEMBL
CHEMBL1255871
ZINC
ZINC000100042059
PDBe Ligand
AXT
Wikipedia
Astaxanthin
PDB Entries
1gka

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentNPDR - Non Proliferative Diabetic Retinopathy / Type 2 Diabetes Mellitus1
1CompletedTreatmentCerebral Stroke / Malondialdehyde / Oxidative Stress1
Not AvailableUnknown StatusBasic ScienceBody Temperature Regulation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
PowderNot applicable1 kg/1kg
CapsuleOral4 mg
TabletOral
Capsule, gelatin coatedOral4 mg
CapsuleOral
TabletOral100 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000667 mg/mLALOGPS
logP7.4ALOGPS
logP8.05ChemAxon
logS-6ALOGPS
pKa (Strongest Acidic)13.07ChemAxon
pKa (Strongest Basic)-3.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area74.6 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity195.98 m3·mol-1ChemAxon
Polarizability73.77 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Ubiquitin protein ligase binding
Specific Function
Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL dimers in the cytoplasm through masking of their nuclear localization signals. On cellular stimulation by immune and proinf...
Gene Name
NFKBIA
Uniprot ID
P25963
Uniprot Name
NF-kappa-B inhibitor alpha
Molecular Weight
35608.65 Da
References
  1. Lee SJ, Bai SK, Lee KS, Namkoong S, Na HJ, Ha KS, Han JA, Yim SV, Chang K, Kwon YG, Lee SK, Kim YM: Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation. Mol Cells. 2003 Aug 31;16(1):97-105. [PubMed:14503852]

Drug created on March 19, 2008 10:36 / Updated on July 10, 2020 21:42

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates